The effect of antibiotic treatment on active trachoma and ocular chlamydia trachomatis infection

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 2, 2003, Pages 209-216

  Mabey, Denise ^a   Solomon, Anthony ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antibiotics; Azithromycin; Chlamydia trachomatis; Tetracycline; Trachoma

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; PLACEBO; TETRACYCLINE;

ANTIMICROBIAL ACTIVITY; BLINDNESS; CATARACT; CHILD HEALTH CARE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL; COCHRANE LIBRARY; COMMUNITY CARE; DRUG EFFICACY; DRUG MECHANISM; EYE INFECTION; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFECTION RISK; MEDICAL RESEARCH; MORBIDITY; NEISSERIA GONORRHOEAE; NONHUMAN; PARASITEMIA; PREVALENCE; REVIEW; RISK REDUCTION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRACHOMA; TREATMENT OUTCOME; URETHRITIS; UTERINE CERVICITIS; WORLD HEALTH ORGANIZATION;

EID: 3042823400     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.2.209     Document Type: Review

References (65)

1. Thylefors B, Negrel AD, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull. World Health Organ. 73, 115-121 (1995).
2. Baral K, Osaki S, Shreshta B et al. Reliability of clinical diagnosis in identifying infectious trachoma in a low-prevalence area of Nepal. Bull. World Health Organ. 77, 461-466 (1999).
3. Lietman TM, Dawson CR, Osaki SY, Zegans ME. Clinically active trachoma versus actual Chlamydial infection. Med. J. Aust. 172, 93-94 (2000).
4. Taylor HR, Siler JA, Mkocha HA, Munoz B, West S. The natural history of endemic trachoma: a longitudinal study. Am. J. Trop. Med. Hyg. 46, 552-559 (1992).
5. Bailey RL, Hampton TJ, Hayes LJ, Ward ME, Whittle HC, Mabey DC. Polymerase chain reaction for the detection of ocular chlamydial infection in trachoma-endemic communities. J. Infect. Dis. 170, 709-712 (1994).
6. Schachter J. Chlamydia trachomatis: the more you look, the more you find-how much is there? Sex. Transm. Dis. 25, 229-231 (1998).
7. Schachter J, Moncada J. Nucleic acid amplification tests to diagnose Chlamydia trachomatis genital infection - the glass is more than half full. In: Chlamydial infections: Proceedings of the tenth international symposium on human chlamydial infections. International Chlamydia Symposium, Antalya, Turkey, (2002).
8. Dawson C, Munoz B, Sheta A, Sallam S, West S, Schachter J. Clinical and laboratory assessment of azithromycin or topical tetracycline for trachoma in the ACT trial in Egypt. In: Proceedings of the fourth Meeting of the European Society for Chlamydia Research. Universitas Helsingiensis, Helsinki, Finland, (2000).
9. Thylefors B. Prevention of blindness - WHO's mission for vision. World Health Forum 19, 53-59 (1998).
10. Grayston JT, Wang SP, Yeh LJ, Kuo CC. Importance of reinfection in the pathogenesis of trachoma. Rev. Infect. Dis. 7, 717-725 (1985).
11. Turner VM, West SK, Munoz B et al. Risk factors for trichiasis in women in Kongwa, Tanzania: a case-control study. Int. J. Epidemiol. 22, 341-347 (1993).
12. Dawson CR, Daghfous T, Messadi M, Hoshiwara I, Schachter J. Severe endemic trachoma in Tunisia. Br. J. Ophthalmol. 60, 245-252 (1976).
13. Courtright P, Sheppard J, Schachter J, Said ME, Dawson CR. Trachoma and blindness in the Nile Delta: current patterns and projections for the future in the rural Egyptian population. Br. J. Ophthalmol. 73, 536-540 (1989).
14. Freyche MJ. Antibiotics and sulfonamides in the treatment of trachoma. Bull. World Health Organ. 2, 523-544 (1950).
15. Future approaches to trachoma control: report of a global scientific meeting (WHO/PBL/96.56). World Health Organization, Geneva, Switzerland, (1997).
16. Global elimination of blinding trachoma. Geneva, World Health Organization 51st World Health Assembly, Resolution 51.11. Text at http://who.int/pbd/trachoma/wha51-e.htm: World Health Organization (1998).
17. Primary healthcare level management of trachoma (WHO/PBL/93.33). Geneva: World Health Organization (1993).
18. Slaney L, Chubb H, Ronald A, Brunham R. In vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi and Chlamydia trachomatis. J. Antimicrob. Chemother. 25(Suppl. A), 1-5 (1990).
19. Scieux C, Bianchi A, Chappey B, Vassias I, Perol Y. In vitro activity of azithromycin against Chlamydia trachomatis. J. Antimicrob. Chemother. 25(Suppl. A), 7-10 (1990).
20. Foulds G, Shepard RM and Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl. A) 73-82 (1990).
21. Panteix G, Guillaumond B, Harf R et al. In vitro concentration of azithromycin in human phagocytic cells. J. Antimicrob. Chemother. 31(Suppl. E), 1-4 (1993).
22. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am. J. Med. 91, 5S-11S (1991).
23. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Azithromycin in the treatment of sexually transmitted disease. J. Antimicrob. Chemother. 25(Suppl. A), 109-114 (1990).
24. Nilsen A, Halsos A, Johansen A et al. A double-blind study of single dose azithromycin and doxycycline in the treatment of Chlamydial urethritis in males. Genitourin Med. 68, 325-327 (1992).
25. Martin DH, Mroczkowski TF, Dalu ZA et al. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. N. Engl. J. Med. 327, 921-925 (1992).
26. Mabey D, Fraser-Hurt N. Antibiotics for trachoma (Cochrane review). Cochrane Database Syst. Rev. CD001860 (2002).
27. Attiah MA, el Kohly AM. Clinical assessment of the comparative effect of terramycin and GS 2989 in the mass treatment of trachoma. Rev. Int. Trach. 50, 11-20 (1973).
28. Darougar S, Jones BR, Viswalingam N et al. Family-based suppressive intermittent therapy of hyperendemic trachoma with topical oxytetracycline or oral doxycycline. Br. J. Ophthalmol. 64, 291-295 (1980).
29. Foster SO, Powers DK, Thygeson P. Trachoma therapy: a controlled study. Am. J. Ophthalmol 61, 451-455 (1966).
30. Peach H, Piper S, Devanesen D et al. Trial of antibiotic eye drops for the prevention of trachoma in school-age Aboriginal children. Annual Report of the Menzies School of Health Research 74-76 (1986).
31. Tabbara KF, Summanen P, Taylor PB, Burd EM, al Omar O. Minocycline effects in patients with active trachoma. Int. Ophthalmol. 12, 59-63 (1988).
32. Woolridge RL, Cheng KH, Chang IH, Yang CY, Hsu TC, Grayston JT. Failure of trachoma treatment with ophthalmic antibiotics and systemic sulfonamides used alone or in combination with trachoma vaccine. Am. J. Ophthalmol. 63(Suppl.), 1577-1586 (1967).
33. Hoshiwara I, Ostler HB, Hanna L, Cignetti F, Coleman VR, Jawetz E. Doxycycline treatment of chronic trachoma. JAMA 224, 220-223 (1973).
34. Tabbara KF, Abu-el-Asrar A, al-Omar O, Choudhury AH, al-Faisal Z. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 103, 842-846 (1996).
35. Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin. Infect. Dis. 24, 363-368 (1997).
36. Schachter J, West SK, Mabey D et al. Azithromycin in control of trachoma. Lancet 354, 630-635 (1999).
37. Bowman RJ, Sillah A, Van Dehn C et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest. Ophthalmol. Vis. Sci. 41, 4074-4079 (2000).
38. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomized controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 342, 453-456 (1993).
39. Ridgway GL. Azithromycin in the management of Chlamydia trachomatis infections. Int. J. STD AIDS 7, 5-8 (1996).
40. Sadiq ST, Glasgow KW, Drakeley CJ et al. Effects of azithromycin on malariometric indices in The Gambia. Lancet 346, 881-882 (1995).
41. Treadway G, Pontani D. Pediatric safety of azithromycin: worldwide experience. J. Antimicrob. Chemother. 37(Suppl. C) 143-149 (1996).
42. Hopkins S. Clinical toleration and safety of azithromycin. Am. J. Med. 91, 40S-45S (1991).
43. Whitty CJ, Glasgow KW, Sadiq ST, Mabey DC, Bailey R. Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr. Infect. Dis. J. 18, 955-958 (1999).
44. Fry AM, Jha HC, Lietman TM et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin. Infect. Dis. 35, 395-402 (2002).
45. Malaty R, Zaki S, Said ME, Vastine DW, Dawson DW, Schachter J. Extraocular infections in children in areas with endemic trachoma. J. Infect. Dis. 143, 853 (1981).
46. West S, Munoz B, Bobo L et al. Nonocular Chlamydia infection and risk of ocular reinfection after mass treatment in a trachoma hyperendemic area. Invest. Ophthalmol. Vis. Sci. 34, 3194-3198 (1993).
47. Dawson CR, Schachter J. Should trachoma be treated with antibiotics? Lancet 359, 184-185 (2002).
48. Thein J, Zhao P, Liu H et al. Does clinical diagnosis indicate ocular chlamydial infection in areas with a low prevalence of trachoma? Ophthalmic Epidemiol. 9, 263-269 (2002).
49. Dawson C, Munoz B, Shama A et al. Antibiotic treatment of trachoma in the Egyptian arm of the ACT trial: laboratory testing and clinical examinations. In: Chlamydial Infections: Proceedings of the Tenth International Symposium on Human Chlamydial Infections. Schachter J, Christiansen G, Clarke IN et al. (Eds). Antalya, Turkey, (2002).
50. Treharne JD. The community epidemiology of trachoma. Rev. Infect. Dis. 7, 760-764 (1985).
51. West SK, Rapoza P. Munoz B, Katala S, Taylor HR. Epidemiology of ocular chlamydial infection in a trachomahyperendemic area. J. Infect. Dis. 163, 752-756 (1991).
52. Bailey R, Duong T, Carpenter R, Whittle H, Mabey D. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol. Infect. 123, 479-486 (1999).
53. Solomon AW, Holland MJ, Burton MJ et al. Strategies for the control of trachoma: an observational study using quantitative PCR. Lancet (2003) (In Press).
54. Holm SO, Jha HC, Bhatta RC et al Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull. World Health Organ. 79, 194-200 (2001).
55. Frick KD, Lietman TM, Holm SO, Jha HC, Chaudhary JS, Bhatta RC. Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull. World Health Organ. 79, 201-207 (2001).
56. Leach AJ, Shelby-James TM, Mayo M et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin. Infect. Dis. 24, 356-362 (1997).
57. Laming AC, Currie BJ, DiFrancesco M, Taylor HR, Mathews JD. A targeted, single-dose azithromycin strategy for trachoma. Med. J. Aust. 172, 163-166 (2000).
58. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nature Med. 5, 572-576 (1999).
59. Munoz B, Solomon AW, Zingeser J et al. Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. Invest. Ophthalmol. Vis. Sci. 44, 1464-1469 (2003).
60. Solomon AW, Akudibillah J, Abugri P et al. Pilot study of the use of community volunteers to distribute azithromcyin for trachoma control in Ghana. Bull. World Health Organ. 79, 8-14 (2001).
61. Bailey R, Lietman T. The SAFE strategy for the elimination of trachoma by 2020: will it work? Bull. World Health Organ. 79, 233-236 (2001).
62. Chern KC, Shrestha SK, Cevallos V et al. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area. Br. J. Ophthalmol. 83, 1332-1335 (1999).
63. Adegbola RA, Mulholland EK, Bailey R et al. Effect of azithromycin on pharyngeal microflora. Pediatr. Infect. Dis. J. 14, 335-337 (1995).
64. Kastner U, Guggenbichler JP. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection 29, 251-256 (2001).
65. Jones BR. The prevention of blindness from trachoma. Trans. Ophthalmol. Soc. UK95, 16-33 (1975).